Search

Your search keyword '"Falcone, Antonietta"' showing total 138 results

Search Constraints

Start Over You searched for: Author "Falcone, Antonietta" Remove constraint Author: "Falcone, Antonietta" Database Unpaywall Remove constraint Database: Unpaywall
138 results on '"Falcone, Antonietta"'

Search Results

1. Supplementary Figure 4 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

2. Supplementary Figure 4 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

3. Supplementary Figure 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

4. Supplementary Figure 4 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

5. Supplementary Figure 4 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

6. Supplementary Figure 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

7. Supplementary Table 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

8. Supplementary Figure 2 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

9. Supplementary Figure 1 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

10. Supplementary Table 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

11. Supplementary Figure 1 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

12. Supplementary Table 1 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

13. Supplementary Figure 2 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

14. Supplementary Table 1 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

15. Supplementary Table 2 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

16. Supplementary Table 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

17. Supplementary Table 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

18. Supplementary Methods from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

19. Supplementary Table 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

20. Supplementary Figure 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

21. Supplementary Figure 5 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

22. Supplementary Figure 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

23. Supplementary Figure 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

24. Supplementary Figure 3 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

25. Supplementary Table 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

26. Supplementary Figure 3 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

27. Supplementary Methods from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

28. Supplementary Figure 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

29. Supplementary Figure 5 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

30. Supplementary Table 2 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

31. Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study

32. Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

33. P-149: Prevalence of type 1 Gaucher disease in patients with multiple myeloma: interim analysis of a prospective, multicentre, observational study

34. Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial

36. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP)

37. Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the ‘Rete Ematologica Pugliese E Basilicata’

38. First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials

39. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

40. Minimal residual disease and log‐reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma

41. First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response

42. Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

43. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response

44. Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian ‘Back to Life’ project

45. Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study

46. Ruxolitinib – better prognostic impact in low-intermediate 1 risk score: evaluation of the ‘rete ematologica pugliese’ (REP) in primary and secondary myelofibrosis

47. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

48. Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns

49. Bendamustine in relapsed/refractory multiple myeloma: the “real-life” side of the moon

50. Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study

Catalog

Books, media, physical & digital resources